In the present study, AAV-α-synuclein (human wildtype) overexpression in rat substantia nigra 54 recapitulates PD-like aberrant STN burst firing, DAergic neurodegeneration and motor dysfunction. Using 55 the AAV-α-synuclein overexpression approach, we investigated the effect of chronic LRRK2 inhibition on 56 α-synuclein-induced neuronal dysfunction. Chronic LRRK2 inhibition had a partial restorative effect on 57 motor function, which was not correlated with any effect on aberrant STN firing, dopaminergic 58 neurodegeneration measured by striatal tyrosine hydroxylase expression, LRRK2 expression, α-synuclein 59 expression or phosphorylation (α-synuclein-pS129). The present findings do not strongly support the 60 mechanistic link between LRRK2 kinase activity and pathological α-synuclein, and further reveal some 61 limitations of the preclinical AAV α-synuclein overexpression model. 62
Methods 63
In vivo experimental methods 64
Ethical statement 65
All experiments were carried out in accordance with the European Communities Council Directive 66 (86/609/EEC) for the care and use of laboratory animals and the Danish legislation regulating animal 67 experiments. 68
Animals 69
Female Sprague Dawley rats were acquired from Taconic Denmark (NTac:SD, n=23 in total). Rats were 70 group housed in humidity (55-65 %) and temperature (22 ± 1.5 ⁰C) controlled conditions in a 12:12 hours 71 light/dark cycle. Water and food were available ad libitum. Female rats were used as experimental subject 72 as they have lower body weight and lower variation in skull size compared to male rats at 26 weeks of age 73 where the experiment was carried out. Lower body weight and variation in skull size are preferred in the 74 in vivo electrophysiological experiments. 75 Viral mediated α-synuclein overexpression in substantia nigra 76
Injection of recombinant adeno-associated-viral vectors (AAV) was performed in 10-12 weeks old animals 77 (weighing 250-300 g). Surgical neuroleptic analgesia was induced with a mixture of Hypnorm® and 78 Dormicum (corresponding to 157 µg/kg fentanyl, 2.5 mg/kg midazolam and 5 mg/kg fluanisone). All 79 incisions were infiltrated with local analgesia (lidocaine). The rats were placed in a stereotaxic frame and 80 the body temperature was maintained at 37.5 ⁰C. After a skin incision, a hole was drilled in os paritalis 81 directly above the substantia nigra pars compacta (SNc) at the following coordinates, according to Paxinos 82 and Watson (2007) : 5.5 mm caudal to bregma and 2.0 mm lateral to the midline. The injection cannula 83 (Hamilton, 30 gauge stainless steel cannula) was slowly lowered into the injection site located 7.2 mm 84 ventral to the brain surface. A unilateral injection of 3 µl AAV viral vector (3 x 10Malvern, PA, USA) containing the transgene for human wildtype (hwt) α-synuclein or an empty vector 86 (CTRL) was performed at a flow rate of 0.2 µl/min. The cannula was left in place for 5 min after the 87 injection to allow diffusion. After the skin was sutured, a 24 hours analgesic treatment protocol was 88 initiated (buprenorphine 0.05 mg/kg every 8 th hour). The transgene expression was driven by a chimeric 89 promoter element containing part of the Cytomegalovirus promoter and a part of the synthetic chicken 90 potentials were amplified (x 10k), band pass filtered (300Hz -5kHz), discriminated and monitored on an 131 oscilloscope and an audio monitor. Spike trains of action potentials were captured and analyzed using 132 Spike 2 v 7.13 software with a computer-based system connected to the CED 1401 (Cambridge Electronic 133 Design Ltd., Cambridge, UK). A minimum of 500 consecutive spikes was used for analysis of basal firing 134
properties. PFE-360 was administrated to the rats per oral 1 hour before the start of the recording session 135 and ended 6 -8 hours post-dosing. 136
At end of the recording session, an iontophoretic ejection of Pontamine Sky Blue was achieved by applying 137 a negative voltage to the electrode allowing visualization of the last recording position using classical 138 histological methods. The recording sites were then retrospectively reconstructed, and neurons were only 139 included in the analysis if the reconstruction provided evidence of the neuron to be within the STN. 140
Single unit recordings data analysis 141
The action potential of glutamatergic neurons in STN is typically short (<2 ms) with a biphasic waveform 142 (Hollerman and Grace, 1992) . Each spike-train was carefully inspected before the analysis using the 143 principle component tools and the overdraw wavemark function in Spike 2 v 7.13, making sure that only 144 spikes from a single neuron were included in the analysis. The signal to noise ratio was always >2:1. Spike 145 trains were analyzed offline using a custom-made script measuring the firing rate and coefficient of 146 variation of the interspike interval (CV ISI). Briefly the CV ISI is defined as the ratio between the standard 147 deviation of the interspike interval and the average interspike interval x 100 (Herrik et al., 2010) . Further, 148 the classification of the neuronal firing pattern was divided into regular, irregular and bursty based on a 149 visual inspection of the autocorrelogram and the discharge density histogram (Tepper et al., 1995 ; 150 Kaneoke and Vitek, 1996) . 151
Ex-vivo biochemical methods 152
Brain sampling 153
At the end of the recording session, the rats were perfused transcardially with 100 ml 0.9 % saline 154 containing 0.3 % heparin. The brain was removed and sectioned on an ice-cold plate. The striata were 155 snap frozen on dry-ice and stored at -80 ⁰C until preparation of tissue lysates for SDS-PAGE and Western 156 blot. The caudal part of the brain containing STN was stored at -20 ⁰C for histological validation of the 157 recording sites. The cerebellum was weighted and snap frozen in a Covaris tube on dry ice and stored at 158 -80 ⁰C until further analysis. 159
SDS-PAGE and Western blot sample preparation 160
Preparation of striatal samples for SDS-page and Western blot was performed as described elsewhere 161 (Andersen et al., 2018a) . 162 SDS-page and Western blot quantification of tyrosine hydroxylase, striatal enriched phosphatase, 163 human wild-type α-synuclein and phosphorylated α-synuclein-S129. 164
Quantification of TH, STEP and hwt-α-synuclein expression and α-synuclein-S129 phosphorylation were 165 done as described elsewhere ((Andersen et al., 2018a). Briefly, the quantification was done using SDS-166 page and subsequent Western blot. Finally, the proteins were visualized quantified by infrared detection 167 using Li-Cor Odyssey CLx (Li-COR, Nebraska, US). 168
Total LRRK2 and phosphorylated LRRK2-S935 quantification 169
Total LRRK2 expression levels and the level of LRRK2 inhibition were quantified using SDS-page and 170 subsequent Western blot as described elsewhere (Andersen et al., 2018b ). The total LRRK2 was quantified 171 for both ipsi-and contralateral striatum and reported as the mean of the two measurements.
Quantification of PFE-360 brain exposure 173
The analysis method is described elsewhere (Andersen et al., 2018a) . Briefly, the quantification of PFE-174 360 brain exposure was performed using a LC-MS/MS coupled to a Waters Acquity UPLC. 175
Statistical analysis 176
Neuronal firing properties (firing rate and CV ISI) data were analyzed using Kruskal-Wallis test with Dunn's 177 corrected p-value for multiple comparison, as they were non-normally distributed. Distributive 178 differences in firing pattern were statistically assessed using Chi-squared analysis. The p-value for multiple 179 chi-squared tests were corrected using the Bonferroni correction (p > 0.0125 was considered significant). 180
Motor behavior and Western blot quantifications (TH, STEP, α-synuclein-pS129, LRRK2 and LRRK2-pS935) 181 data were all normally distributed and were analyzed using a one-way ANOVA test with Tukey's post hoc 182 multiple comparison. Statistical analysis of human α-synuclein overexpression and unbound PFE-360 183 exposure were done using an unpaired t-test. All statistics and figures were made in GraphPad Prism® 184 7.03. All values are presented as mean ± SEM.
Results 186
Chronic PFE-360 dosing modulates AAV-α-synuclein-induced motor deficit 187
In our effort to evaluate the therapeutic preclinical potential of chronic LRRK2 inhibition, we first tested 188 the effect of PFE-360 (7.5 mg/kg BID) on motor symmetry in the cylinder test. Overall, there was a 189 statistically significant effect on the forepaws ratio across groups (Fig. 1A) . Multiple Analysis of the spontaneous locomotor activity 5-7 hours after the last dosing did not show any overall 196 statistical effect of either the viral vector or the treatment, although a trend for reduced locomotor activity 197 was observed in animals injected with AAV-α-synuclein compared to an empty vector (Fig 1B) . 198 AAV-α-synuclein-induced aberrant STN burst firing is not attenuated by chronic LRRK2 inhibition using 199
PFE-360 200
To investigate the modulatory effect of repeated LRRK2 inhibition on STN burst firing induced by hwt α-201 synuclein overexpression in substantia nigra, rats were repeatedly dosed with PFE-360 for 10-12 weeks 202 following viral injection. The electrophysiological properties of putative glutamatergic neurons in STN 203 were recorded at the end of the treatment period, and 1-8 hours following the last dose. A total of 400 204 putative glutamatergic STN neurons from 22 rats divided into 4 groups were included in the final analysis 205 (Fig. 1C-F) . Overall, comparison of the STN firing pattern revealed a significant group effect in the 206 distribution of regular, irregular and bursty firing neurons between groups and a significant group effect 207 in the CV ISI ( Fig. 1D + E) . Multiple comparisons revealed that overexpression of α-synuclein significantlyincreased the proportion of burst firing neurons and the CV ISI compared to an empty vector in vehicle-209 treated animals. In empty vector-injected animals, chronic dosing with PFE-360 7.5 mg/kg BID did not 210 alter the relative distribution of the firing pattern or the CV ISI (CTRL vehicle vs. CTRL PFE-360 7.5 mg/kg). 211
In AAV-α-synuclein injected animals, chronic dosing with PFE-360 did not have any significant effect on 212 the relative distribution of the firing pattern or the CV ISI. The CV ISI was significantly increased compared 213 to CTRL PFE-360, to a level comparable to α-syn PFE-360. The relative distribution of firing pattern of α-214 synuclein was not significantly altered compared to CTRL PFE-360 or α-synuclein vehicle groups. The firing 215 rate was not overall significant different between groups (Fig. 1F) . 216 Striatal LRRK2 expression is not decreased following chronic LRRK2 inhibition 217
Evaluation of the impact of PFE-360 on total LRRK2 expression levels in striatum revealed an overall 218 significant difference between groups ( Fig. 2A + B) . Post hoc analysis revealed no significant effect of AAV-219 α-synuclein overexpression in vehicle treated rats, nor was there any significant effect of PFE-360 220 treatment in CTRL rats. However, PFE-360 treatment in AAV-α-synuclein overexpressing rats significantly 221 decreased the LRRK2 expression level compared to vehicle treated α-synuclein overexpressing rats. There 222 was no statistical difference between PFE-360 treated CTRL and α-synuclein rats. 223 PFE-360 exposure profile and target occupancy in rat brain 224 LRRK2 engagement and kinase inhibition in striatum of PFE-360 6-8 hours post-dosing was evaluated using 225 SDS-page and Western blotting (Dzamko et al., 2010 (Dzamko et al., , 2012 Nichols et al., 2010) . Viral α-synuclein 226 overexpression did not impact levels of LRRK2-pS935 or total LRRK2 ratio (Fig. 2C) . In CTRL and α-synuclein 227 rats dosed with PFE-360 significant decreases in LRRK2-pS935 to total LRRK2 ratio were observed. The 228 result suggests that extended dosing of PFE-360 at 7.5 mg/kg for 10-12 weeks gives full LRRK2 kinase 229 inhibition 6-8 hours post-dosing. A single rat exhibiting a PFE-360 exposure level approximately 3 x IC50, 230 suggestive of 70% inhibition at 8 hours post-dosing, was nevertheless included in the study (Fig. 2D) . The calculated LRRK2 IC50 value and inhibition level is based on a single dose study using 7.5 mg/kg PFE-360 232 (Andersen et al., 2018a). Based on the exposure levels following a single PFE-360 dose of 7.5 mg/kg, the 233 average level of LRRK2 inhibition in the current study is estimated to be from 100 % to 50 % over 24 hours, 234 fluctuating between 100 % at 1-10 hours post-dosing and 100-50 % at 10-12 hours post-dosing (data 235 shown elsewhere (Andersen et al., 2018a) ). 236 
0011) shows increased proportion of bursty neurons in α-synuclein overexpressing rats in both treatment groups. (F) The average firing rate of STN neurons is not significantly different between groups (Kruskal-Wallis test, p =0.11). D-F: (N: number of animals; n: number of neurons; CTRL veh (N = 5, n = 98), α-synuclein veh (N = 6, n = 99), CTRL PFE-360 (N = 6, n = 90) and α-synuclein PFE-360 (N = 6, n = 113). Tukey's multiple comparison is

Figure 2 -Striatal LRRK2 expression is not changed by PFE-360 treatment despite full LRRK2 inhibition. (A) Western blot analysis of total LRRK2 and phosphorylated LRRK2-S935 (LRRK2-pS935) after 10-12 weeks chronic PFE-360 dosing. The tissues were collected 6-8 hours after last dosing. i = ipsilateral to the viral injection and c = contralateral to the viral injection. (B) Quantification of Western blots shows that chronic PFE-360 treatment did not affect LRRK2 expression in CTRL rats compared to vehicle treatment. In α-syn rats, PFE-360 treatment significantly lowered LRRK2 expression compared to vehicle treatment, although each α-syn group did not differ significantly from their respective CTRL group (one-way ANOVA, p = 0.0032). (C) The LRRK2-pS935 to total LRRK2 ratio was used as a measure of target engagement. At full inhibition, the ratio is typically <0.1 and was achieved in both CTRL and α-syn rats treated with PFE-360 (one-way ANOVA, p <0.001). (D) Unbound PFE-360 brain concentrations 6-8 hours post-dosing. IC50 of PFE-360 was previously calculated to 2.3 nM giving theoretical 99 % LRRK2 inhibition at 23 nM (unpaired t-test, p = 0.85). CTRL veh, CTRL PFE-360 and α-syn veh; N = 5, α-syn PFE-
LRRK2 inhibition does not attenuate the loss of TH expression in striatum induced by α-synuclein 237 overexpression 238
Neurodegenerative processes induced by AAV-α-synuclein overexpression were assessed indirectly by 239 quantifying the expression level of TH in striatum. Overall, there was a significant effect of groups on 240 striatal TH expression levels (Fig. 3A + B) . Post hoc analysis revealed a significant loss of striatal TH induced 241 by AAV-α-synuclein overexpression compared to an empty vector independently of treatment. 242 
Figure 3 -Striatal neurodegenerative processes and α-synuclein phosphorylation are not halted by chronic LRRK2 inhibition (A) Western blot analysis of tyrosine hydroxylase (TH) and human wild-type α-synuclein (hwt α-syn) (left) as well as phosphorylation of α-synuclein-S129 (α-syn pS129) (right). i = ipsilateral to the viral injection and c = contralateral to the viral injection. (B) Quantification of TH expression from ipsi-and contralateral striatum normalized to STEP46 and presented as percentage of contralateral striatum shows a significant loss of TH expression in α-syn overexpressing rats in both treatment groups (one-way ANOVA, p < 0.001). (C) The expression level of hwt α-synuclein normalized to STEP46 is not significantly different between groups (unpaired t-test, p = 0.22). (D) The α-synuclein-S129 phosphorylation from ipsi-and contralateral striatum normalized to STEP46 and presented as percentage of contralateral striatum is not significantly different between groups (one-way ANOVA, p = 0.076). CTRL veh, CTRL PFE-360 and α-syn veh
LRRK2 inhibition does not affect human wt α-synuclein expression or phosphorylation of total α-243 synuclein 244
The overexpression of hwt α-synuclein was not significantly different between PFE-360 and vehicle-245 treated animals (Fig. 3A + C) . The levels of pS129-α-synuclein in the striatum were overall not significantly 246 different across groups (Fig 3A + D) . A trend for increased expression was observed following AAV-α-247 synuclein overexpression compared to CTRL animals although this was not significant. Chronic LRRK2 248 inhibition with PFE-360 did not impact α-synuclein-pS129 levels compared to vehicle in CTRL or AAV-α-249 synuclein rats. 250
Discussion 251
Firstly, the findings suggest that the use of our current preclinical PD model in terms of predicting LRRK2 252
inhibitor efficacy in the clinic should be highly cautioned. Secondly, further investigation into mechanisms 253 underlying these differences between models and investigators is needed before any solid conclusions 254 can be made on the translational value of our current preclinical PD model. in the AAV-α-synuclein rat model is reported to be normalized by acute LRRK2 inhibition using PFE-360 297 (Andersen et al., 2018a) . In the present study, all putative STN neurons were recorded under 70 -100% 298 LRRK2 inhibition (based on theoretical back calculations of brain exposure over time (data not shown)). 299
The discrepancy between the effect of acute and chronic LRRK2 inhibition on STN firing properties further 300 supports induction of downstream adaptation to PFE-360 after long term exposure, which was also 301 observed in the locomotor test. 302
We further showed that chronic treatment with PFE-360 did not have any impact on DAergic 303 neurodegeneration, striatal hwt-α-synuclein expression or striatal α-synuclein-pS129 level induced by 304 AAV-α-synuclein overexpression in substantia nigra and associated pathways. These findings contrast 305 findings by Daher et al who reported protection of DAergic neurons from α-synuclein-induced 306 neurodegeneration after chronic treatment with a similar LRRK2 inhibitor chemotype (Daher et al., 2015) . 307
A possible explanation for this discrepancy is related to the different design of the respective studies. Although the viral overexpression model has considerably increased our understanding of α-synuclein-332 induced alterations in the basal ganglia circuitry, the α-synuclein preformed fibrils model has been 333 recently suggested to represent a more faithful model of idiopathic PD (Duffy et al., 2018) , and may 334 therefore be highly valuable to further validate LRRK2 as a therapeutic target for idiopathic PD.
Summary 336
We have demonstrated that chronic LRRK2 inhibition induced a partial reversal of the motor dysfunction 337 in the AAV-α-synuclein rat model of PD. However, this effect was not associated with any beneficial effect 338 on STN burst firing or loss of striatal TH expression. The discrepancies between previously reported acute 339 effects and the present chronic effects of LRRK2 inhibition are likely to be dependent on compensatory 340 mechanisms after chronic LRRK2 inhibition. Nevertheless, the improvement in motor function remains an 341 interesting finding. In this respect, further studies in other preclinical models such as the α-synuclein PFF 342 model may prove valuable. 343
In the search for the precise mechanisms underlying a putative interaction between LRRK2 and α-344 synuclein, changes in synaptic plasticity and vesicular trafficking seems to play a pivotal role in model 345 systems manipulating neuronal and non-neuronal LRRK2 kinase function, respectively. Such changes 346 might result in wanted or unwanted effects. It was previously described that LRRK2 is involved in synaptic 347 plasticity and that it is dysregulated in the parkinsonian state 
